Polaris Partners

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

The HealthCentral Network, Inc. owns and operates Web sites and multimedia affiliate properties that provide medical information, personalized tools and resources, and connections to a community of experts and patients. The company was formerly known as ChoiceMedia, Inc. The HealthCentral Network, Inc. was founded in 1999 and is headquartered in Arlington, Virginia.

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Advion is a global company that offers a variety of systems and consumables for life science research. Its clientele is comprised of pharmaceutical companies, government life science research agencies, and universities. Advion provides a diverse portfolio of microfluidic and mass spec-based products for the life science industry. It was founded in 1993. The company is headquartered in New York, United States.

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

FREEjit, Inc. is in Stealth mode. The company was incorporated in 2010 and is based in Newport Beach, California.

Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Qualaroo is a user research tool for UX designers working in SaaS space. It enables companies to gain valuable insights from their prospects and customers at the moment when they are using the website or app. Qualaroo makes it possible to target prompts by user behavior, specified needs, demographics, or any other internal data. They call these prompts Nudges that can be used to get insights about visitors and influence their behavior.

Wellthy, Inc. provides a concierge service that helps individuals and families to manage and coordinate care for chronically ill, aging, or disabled loved ones using its platform in the United States. It operates a network of family caregivers to help individuals and families find, vet, and coordinate care, as well as provides assistance in the areas of legal, medical, financial, and housing-related issues. The company serves people with aging-related complications, such as dementia and Alzheimer’s, diabetes, heart disease, spinal injuries, and cancer. The company was incorporated in 2014 and is headquartered in New York, New York.

Transform Pharmaceuticals was a pharmaceuticals company specializing in the discovery of improved formulations and novel crystalline forms of drug molecules. Transform’s product portfolio included Topiramate, an anti-epileptic drug. The company was acquired by Johnson & Johnson in 2005. The company was founded in 1998.

e-Rewards®, Inc. (ERI) is the global leader in permission-based digital data collection and reporting. From its inception in 1999, e-Rewards, Inc. has become recognized in the market research industry for setting high quality standards through the combination of innovative technology and proven research practices – all toward helping clients discover insights that lead to greater understanding. With over 1,200 employees worldwide and 6 million panelists around the globe, that “world of understanding” is becoming more and more attainable. The company has 25 offices around the world and operates through its business units Research Now, e-Miles, Peanut Labs, Conversition and iPinion, Inc., and is headquartered in Plano, Texas.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

e-Rewards®, Inc. (ERI) is the global leader in permission-based digital data collection and reporting. From its inception in 1999, e-Rewards, Inc. has become recognized in the market research industry for setting high quality standards through the combination of innovative technology and proven research practices – all toward helping clients discover insights that lead to greater understanding. With over 1,200 employees worldwide and 6 million panelists around the globe, that “world of understanding” is becoming more and more attainable. The company has 25 offices around the world and operates through its business units Research Now, e-Miles, Peanut Labs, Conversition and iPinion, Inc., and is headquartered in Plano, Texas.

Bark & Co is the handiwork of Matt Meeker, Henrik Werdelin and Carly Strife. Brought together by their love of all things canine, these three launched Bark & Co’s first product, BarkBox, with little thought as to how popular it was going to be. BarkBox is a subscription e-commerce and content company for dog-lovers. As BarkBox grew, so did their understanding of the loyal dog parents that loved their monthly box of goodies. The success of the box led to the creation of Bark & Co, a company that is dedicated to building products that foster the health and happiness of dogs everywhere.

Trusted by 25% of the Fortune 100, Twistlock is the most complete, automated and scalable container cybersecurity platform. From precise, actionable vulnerability management to automatically deployed runtime protection and firewalls, Twistlock protects applications across the development lifecycle and into production. Purpose built for containers, serverless, and other leading technologies - Twistlock gives developers the speed they want, and CISOs the control they need. Founded in 2015 by CEO Ben Bernstein and VP R&D Dima Stopel, Twistlock is privately held with funding from Polaris Partners, 1011 Ventures, Rally Ventures, YL Ventures and Dell Technologies Capital. Twistlock is headquartered in Portland, Oregon with offices in New York City, Baton Rouge, Louisiana, London, and Herzliya, Israel.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Bark & Co is the handiwork of Matt Meeker, Henrik Werdelin and Carly Strife. Brought together by their love of all things canine, these three launched Bark & Co’s first product, BarkBox, with little thought as to how popular it was going to be. BarkBox is a subscription e-commerce and content company for dog-lovers. As BarkBox grew, so did their understanding of the loyal dog parents that loved their monthly box of goodies. The success of the box led to the creation of Bark & Co, a company that is dedicated to building products that foster the health and happiness of dogs everywhere.

In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely new molecules and breakthrough technologies for results you can see from across the room.

Bitium is a Santa Monica-headquartered provider of cloud-based identity and access management solutions, including single sign-on, password management, and analytics for small, medium and enterprise businesses. Founded in 2012, the company aims to give growing companies the ability to manage access to all of their web-based applications -- including Google Apps and Office 365, as well as social networks and CRM, collaboration and marketing tools -- in one place without hindering employee adoption of these applications. Organizations such as GroupM, Fullscreen, Movember and Demand Media use Bitium for an easy-to-use solution that delivers increased flexibility and security. Bitium is backed by Polaris Partners, Resolute VC, Double M Partners, Karlin Ventures, Social Leverage and a group of strategic investors in the enterprise cloud space.

Silicon Optix is a fabless semiconductor company, supplier of warping integrated circuit (IC) technology – eWARP™. eWARP digital distortion correction allows manufacturers to complement optics with sophisticated electronics imaging in order to achieve superior system designs and add new compelling features to products while reducing cost and complexity of optical systems. Silicon Optix has the only mainstream geometry processing IC in volume production to date. Over seven years of research and development invested in IC design, system design and optics have given Silicon Optix the expertise to be the leader in this emerging technology with large market opportunities.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

EXOS Physical Therapy and Sports Medicine, LLC provides athletic training and physical therapy services. The company was formerly known as D1 Sports Medicine, LLC and changed its name to EXOS Physical Therapy and Sports Medicine, LLC in August 2017. EXOS Physical Therapy and Sports Medicine, LLC was incorporated in 2010 and is based in Franklin, Tennessee. As of August 25, 2017, EXOS Physical Therapy and Sports Medicine, LLC operates as a subsidiary of Exos Partners, LLC.

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Lob automates direct mail for modern businesses. More than 7,000 companies use Lob’s APIs to move faster and create new growth opportunities. Lob’s APIs dramatically reduce mail processing time, reclaiming thousands of hours and improving data quality. One in four households in the U.S. have received mail generated through Lob’s platform. Headquartered in San Francisco, Lob is backed by leading investors including Y Combinator, First Round Capital and Polaris Partners.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

We exist so you can have the art you love. This means giving you easy access to incredible art images and top-notch craftsmanship. Because when you find art you love, you'll love your space more... and that's what it's all about. We work with passion to bring you the world's largest art collection. Whatever your interest, your décor style, your inspiration – we're sure to have that piece you can't live without. We believe art is dynamic, personal and connected to now, and the experience of buying and living with it should be too. From the moment you browse our site to the day your art is delivered, our team has one goal in mind: to delight you every step of the way.

WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals. WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.

Frictionless Commerce delivers supplier relationship management software to the purchasing organizations. It offers Sourcing software, an enterprise sourcing platform that minimizes the cost of acquisition for various direct and indirect materials, services, and capital equipment. The company serves banking, insurance, professional services, consumer products, discrete manufacturing, life sciences, telecommunications, and utilities markets. Frictionless Commerce, Inc. was founded in 1998 and is based in Newton Square, Pennsylvania with an additional office in London, England. As of June 5, 2006, Frictionless Commerce, Inc. is a subsidiary of SAP AG.

Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Ajax Health is a Private equity and venture capital firm specializing in all stages of a company’s lifecycle. It seeks to invest in innovative medical device companies, medtech, healthcare services, digital health, biotechnology and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. Ajax Health was founded in 2017 and is based in Menlo Park, California with an additional office in New York City, New York.

Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.

CliQr Technologies, Inc. develops a single platform for modeling, deploying, and managing applications across physical, virtual, and cloud environments. It offers CliQr CloudCenter, an application-defined management platform that provides infrastructure resources and deploys application components and data across datacenter, private, and public cloud environments. The also provides solutions for application migration, IT-as-a-Service, capacity augmentation, DevOps automation, and service providers. It offers its solutions through reseller partners worldwide. The company was founded in 2010 and is based in San Jose, California. As of April 15, 2016, CliQr Technologies, Inc. operates as a subsidiary of Insieme Networks, Inc.

Since 1996, Cityworks® has been streamlining the way agencies manage public infrastructure and property by combining the power and flexibility of a Geographic Information System (GIS) with the business logic of asset management, permitting and licensing. Recognizing the Geodatabase as an authoritative system of record for land and asset data, Cityworks leverages the ArcGIS® Location Platform [Esri®] to manage workflow, schedule resources and prioritize activities—saving time, optimizing communication and improving operational efficiencies. Time-tested and proven technology, the Cityworks Web GIS-centric platform is Empowering GIS® at more than 600 organizations around the world.

Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

PublicEarth, launched in November 2009, is a free wiki database of and about locations, generated and updated by users. On the site, people create and maintain PlaceBook personal atlases - which organize and manage their personal locations for ease in sharing, searching, travel planning and activity discovery. In May 2009 PublicEarth began developing a stealth "phase 2" which launched in private beta in August 2010. Originally called PlaceBook (or, famously, PlacéBoök), after threats from Facebook, they changed their landmark travel product TripTrace. In February 2010 PublicEarth was sold to an undisclosed recipient, and separated from the TripTrace website. CEO Rubin purchased the TripTrace project and created a new company TripTrace, Inc. to deliver on the vision.

ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Engine Biosciences Pte. Ltd. develops a validated platform for drug discovering, developing combination therapeutics, and cellular reprogramming. The company's artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks. It provides test therapies that specifically target genetic interactions, and make analyses and predictions for precision medicine applications. The platform provides drug discovery, such as target discovery, drug repositioning, repurposing, pathway, and massive online analysis (MoA) analysis. It caters to the American fortune 500 companies and research institutions. The company was founded in 2014 and is based in Singapore.

Upland Localytics is a mobile app analytics and marketing platform. It gives companies the insights and tools they need to improve their mobile app acquisition, engagement, and retention efforts. It provides a family of cloud-based enterprise work management software applications for information technology, process excellence, finance, professional services, and marketing functions within organizations. The company's platform is used in more than 6,000 apps on more than 2 billion devices by companies such as Live Nation, HSN, Comcast, and The New York Times.

OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required. Akili is based in Boston, Massachusetts.

Infinite Power Solutions, Inc. (IPS), a U.S. based clean-technology company, is the global leader in developing, marketing and manufacturing solid-state, rechargeable thin-film micro-energy storage devices for a variety of micro-electronic applications. Founded in 2001, IPS is privately held with corporate headquarters and manufacturing facilities in the western suburbs of [Denver, CO](http://www.crunchbase.com/maps/search?range=10&geo=denver,+co). The company has completed the build-out of the world's first volume manufacturing facility dedicated to the production of its revolutionary thin-film micro-energy cell (MEC(TM)) products (often referred to as thin-film batteries). IPS has recently commenced pre-production activities at this state-of-the-art facility to address growing demand among customers in the wireless sensor, active RFID, powered smart card, medical device, consumer electronics, automotive and civil/military/aerospace markets

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.

Qradar, a network security management solution that includes log, threat and compliance management

PartsSource provides the medical equipment service industry with proprietary software solutions related to the acquisition and life cycle management of medical repair parts. The company has been recognized by clinical engineers and healthcare executives alike for its unique ePartsFinder® application for its ability to increase department efficiencies while reducing costs through its award-winning SmartPrice™ technology.

Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely new molecules and breakthrough technologies for results you can see from across the room.

Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Its device is designed to target and inactivate the most active sweat glands. The company was founded in 2016 and is headquartered in San Francisco, California.

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

6waves Global Mobile and Social Games Publishing

Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. The company was founded in 2019 and headquartered in Waltham, Massachusetts.

AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

Simon Data, Inc. develops and distributes a performance marketing platform. The company offers core data ingestion, personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis solutions. Simon Data, Inc. was formerly known as Radico, Inc. and changed its name to Simon Data, Inc. in November 2013. The company was founded in 2013 and is based in Brooklyn, New York.

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.

Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Trusted by 25% of the Fortune 100, Twistlock is the most complete, automated and scalable container cybersecurity platform. From precise, actionable vulnerability management to automatically deployed runtime protection and firewalls, Twistlock protects applications across the development lifecycle and into production. Purpose built for containers, serverless, and other leading technologies - Twistlock gives developers the speed they want, and CISOs the control they need. Founded in 2015 by CEO Ben Bernstein and VP R&D Dima Stopel, Twistlock is privately held with funding from Polaris Partners, 1011 Ventures, Rally Ventures, YL Ventures and Dell Technologies Capital. Twistlock is headquartered in Portland, Oregon with offices in New York City, Baton Rouge, Louisiana, London, and Herzliya, Israel.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Swiftly develops enterprise software that helps transit agencies and cities improve urban mobility. Built by transportation experts for transportation professionals, the Swiftly platform harnesses billions of data points and sophisticated algorithms to improve transit system performance, service reliability, and real-time passenger information. Swiftly’s technology platform is installed in over 50 cities from coast to coast, improving transportation services for millions of riders each day. Swiftly was founded on 2014 and is headquartered in San Francisco, California.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

MessageGate, Inc. provides enterprise email governance software and services. Its products include MessageGate archive categorization, which enables organizations to archive messages by analyzing email traffic as it is sent and received; MessageGate policy enforcement, a policy management solution that can enforce corporate messaging polices and prevent intentional or inadvertent breaches; email filtering, which detects lies in an email, and analyzes header and connection information contained in inbound email traffic and blocks those that are not truthful; and activity profiles, which provide companies with detailed visibility into their current messaging traffic and their email archive contents. The company also offers operational and forensic email analysis; retrospective email archive categorization; and consulting services. Through its consulting services, MessageGate, Inc. provides assistance in the installation and customization of the MessageGate solutions. MessageGate, Inc. was incorporated in 2001 and is based in Bellevue, Washington.

Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Chiaro Networks, Inc. engages in the design, manufacture, and delivery of Internet protocol/multi protocol label switching in the United States.

Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.